16/01/2018 - 08:27 StockMarketWire
ValiRx has provided an update on the clinical progress of an anti-cancer compound developed by ValiSeek, a joint venture...
16/01/2018 - 07:00 RNS
RNS Number: 9423B ValiRx PLC 16 January 2018 VALIRX PLC ("ValiRx", the "Company" or the "Group") VALISEEK CLINICAL UPDATE (VAL401) "Positive Impact of Patient Quality of Life and Immune Competency in VAL401 Phase II Clinical Trial" London, UK ., 16 January 2018: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company , is pleased...
16/01/2018 - 00:00 BRR Media
11/01/2018 - 08:03 StockMarketWire
ValiRx, the clinical stage biotechnology company, has received patent approval in the US for its lead therapeutic compoun...
Join interactive investor
- £22.50 fixed quarterly charge includes £22.50 in trading credits
- £10 per trade or £6 for frequent traders
- No % platform fees
- £1 per trade for regular investment or dividend reinvestment